Selecting the RIGHT Patient for Systemic Therapy in cSCC: A Care Team Forum

Program Overview

The recent approval of the first immunotherapeutic agent for cutaneous squamous cell carcinoma (cSCC) is changing the way healthcare providers treat patients with inoperable cSCC. In this roundtable discussion, a survivor of cSCC draws upon his experience with the cancer when surgery and chemotherapy failed him, as our multidisciplinary faculty panel focus on how to optimally select patients with cSCC for treatment with immunotherapy.

Credit Expired

Target Audience

The intended audience for this activity is Mohs surgeons, medical oncologists, and dermatologists who manage patients with cutaneous squamous cell carcinoma (cSCC).

Educational Objectives

Upon completion of this activity, participants should be better able to:

Identify patients with cutaneous squamous cell carcinoma (cSCC) who are unlikely to be cured by surgery to expedite appropriate workup, multidisciplinary team collaboration, and referral for systemic therapy (including immunotherapy) to improve patient outcomes and quality of life
Incorporate shared decision making (SDM), quality of life assessment and management, and collaborative care for patients with cSCC to improve patient outcomes

Activity Faculty

Chrysalyne D. Schmults, MD, MSCE

Associate Professor, Dermatology
Harvard Medical School
Director, Mohs and Dermatologic Surgery Center
Dana-Farber/Brigham and Women’s Cancer Center
Boston, MA

Omid Hamid, MD

Chief, Translational Research and Immunotherapy
Director, Cutaneous Oncology
The Angeles Clinic and Research Institute
Los Angeles, CA

Anokhi Jambusaria, MD, MSCE, FAAD

Assistant Professor, Division of Dermatology
Department of Internal Medicine
The University of Texas
Austin Dell Medical School
Austin, TX

Featured RMEI CE Activities – Earn CE Credit(s)

Selecting the RIGHT Patient for Systemic Therapy in cSCC: A Care Team Forum

Program Overview

Target Audience

Educational Objectives

Activity Faculty

Chrysalyne D. Schmults, MD, MSCE

Omid Hamid, MD

Anokhi Jambusaria, MD, MSCE, FAAD

Advances in Precision Medicine for Relapsed/Refractory Diffuse Large B-Cell Lymphoma Care: A Care Team Forum®

Refining Management of CMV After Transplant: Exploiting Recent Advances to Alleviate Patient Burden

Overcoming Obstacles to Optimal Multiple Sclerosis (MS) Care in Minority Patient Populations

Subscribe